Medley Pharmaceuticals Ltd. v. Khandelwal Laboratories Ltd.

In the fiercely competitive pharmaceutical industry, brand names can make or break a product. But what happens when a company tries to claim ownership over a prefix that every other player in the market is already using? The Bombay High Court's decision in the Medley Pharmaceuticals vs Khandelwal Laboratories case serves as a powerful reminder that not every recognizable word or syllable can be monopolized, especially when it originates from a widely-used chemical compound.

Medley Pharmaceuticals Ltd., the plaintiff, approached the court seeking an interim injunction against Khandelwal Laboratories Ltd. in a passing off suit. The dispute centered on trademarks that shared the prefix 'CEF,' a prefix commonly derived from the chemical compound Cefixime, a well-known antibiotic used across the pharmaceutical industry. Medley Pharmaceuticals claimed that Khandelwal Laboratories' use of similar 'CEF'-prefixed marks amounted to passing off, essentially arguing that consumers would be confused into believing the products were theirs. The plaintiff sought to halt the defendant's use of these marks pending the resolution of the suit.

Medley Pharmaceuticals argued that their 'CEF'-prefixed trademarks had acquired distinctiveness and reputation in the market, giving them exclusive rights to use this prefix in connection with their pharmaceutical products. They contended that the defendant's adoption of similar marks would mislead consumers and dilute their brand identity. On the other side, Khandelwal Laboratories countered that the 'CEF' prefix was not unique to Medley at all. The defendant pointed out that this prefix was derived from the chemical name Cefixime and was commonly used across the pharmaceutical industry by numerous manufacturers. The core legal friction thus revolved around a fundamental question: can a company claim proprietary rights over a prefix that is essentially a public chemical reference, widely adopted by competitors?

The Bombay High Court dismissed Medley Pharmaceuticals' motion for an interim injunction, ruling decisively in favor of Khandelwal Laboratories. The court found that trademarks bearing the 'CEF' prefix are commonly used across the pharmaceutical industry, reflecting the widespread adoption of prefixes and suffixes derived from chemical compounds like Cefixime. Critically, the court held that Medley Pharmaceuticals had failed to establish exclusivity or reputation for their mark. Because the prefix was generic to the industry and not distinctive to any single player, the plaintiff could not demonstrate the kind of proprietary claim necessary to succeed in a passing off action. The interim injunction was denied, allowing Khandelwal Laboratories to continue using their similar marks.

For founders and IP professionals in the pharmaceutical space, this case delivers a clear and actionable lesson: do not rely on common chemical prefixes or suffixes to build your brand identity. When a prefix is derived from a widely-used chemical compound like Cefixime, it is considered part of the industry's common vocabulary, and no single company can claim exclusive ownership over it. To build a protectable trademark, invest in distinctive, coined, or arbitrary elements that set your brand apart, rather than leaning on generic chemical references. In passing off actions, courts will look for evidence of genuine exclusivity and reputation, not just prior use of a universally adopted prefix. Choose your marks wisely, because in pharma, the chemistry of branding is just as important as the chemistry of your product.